TXP Innovations LLC dba Tex Peptides – FDA Warning Letter, Aug 3, 2026

TXP Innovations LLC, operating as Tex Peptides, received an FDA Warning Letter dated August 24, 2026, following a July 2026 review of its website. The agency found that the company is marketing several unapproved and misbranded drug products, specifically injectable peptides including Semaglutide, Tirzepatide, Retatrutide, and Tesamorelin. Despite labeling these items for "research use only," the FDA determined they are intended for human use based on website claims regarding the treatment of conditions such as type 2 diabetes, obesity, and metabolic disorders. The FDA emphasized that these injectable products pose significant public health risks as they bypass the body"s natural defenses against toxins. Under the Federal Food, Drug, and Cosmetic Act, introducing these unapproved new drugs into interstate commerce is a legal violation. The company also sold bacteriostatic water intended for the reconstitution of these peptides, further indicating their use as injectable drugs for humans. TXP Innovations is required to respond within 15 business days with a detailed plan describing how they will correct these violations and prevent their recurrence. The response must include supporting documentation for all corrective actions taken. Failure to address these issues promptly may result in legal consequences, including product seizures or injunctions.